You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: RE33239


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE33239
Title: Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
Abstract:A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, in antioxidant and a buffer, the solution or suspension having a pH value of from 4 to 7 and being contained in a plastic bottle under an inert gas, the plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.
Inventor(s): Halskov; Soren (Virum, DK)
Assignee: Farmaceutisk Laboratorium Ferring A/S (Vanlose, DK)
Application Number:07/350,891
Patent Claim Types:
see list of patent claims
Formulation; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent RE33239: A Comprehensive Analysis

Introduction

When analyzing a patent, particularly a reissued patent like the United States Patent RE33239, it is crucial to delve into its scope, claims, and the broader patent landscape. This article will provide a detailed examination of these aspects, helping business professionals and inventors navigate the complexities of patent law and strategy.

What is a Reissued Patent?

A reissued patent is a new patent that is issued to replace an original patent, often due to errors or omissions in the original patent. This process allows patent holders to correct or expand their original claims, which can significantly impact the patent's scope and validity[2].

Patent Scope and Claims

Definition of Patent Scope

Patent scope refers to the breadth and depth of protection afforded by a patent. It is a critical factor in determining the patent's value and its potential impact on the market. Metrics such as independent claim length and independent claim count are often used to measure patent scope[3].

Analyzing Claims of RE33239

To understand the scope of RE33239, one must carefully examine its claims. Here are some key points to consider:

  • Independent Claims: These are the core claims that define the invention without referencing other claims. Longer and more detailed independent claims generally indicate a narrower but more specific scope.
  • Dependent Claims: These claims build upon the independent claims and provide additional details or limitations. A higher number of dependent claims can indicate a broader scope but also increases the complexity and potential for challenges.
  • Claim Language: The clarity and specificity of the claim language are vital. Broader claims with vague language can lead to disputes over patent validity and scope[3].

Patent Landscape and Precedents

Obviousness-Type Double Patenting (ODP)

ODP is a critical concept in patent law that prevents an inventor from securing a second, later-expiring patent for an invention that is obvious in view of a prior patent. This principle is particularly relevant when analyzing reissued patents, as seen in the case of In re Cellect LLC, where the Federal Circuit discussed the implications of ODP on patent term adjustments and terminal disclaimers[1].

Impact of ODP on RE33239

For RE33239, any analysis must consider whether the claims could be deemed obvious variants of prior patents. If the claims are found to be obvious over earlier patents, they may be subject to ODP, potentially limiting their validity and scope.

Determining Inventorship

Conception and Reduction to Practice

Inventorship is another crucial aspect of patent law. The conception of an invention, defined as the formation of a definite and permanent idea of the complete and operative invention, is key. This concept must be sufficiently clear to allow one with ordinary skill in the field to reduce it to practice without undue experimentation[4].

Implications for RE33239

Ensuring that the inventors listed for RE33239 are the true and sole inventors is essential. Misattribution of inventorship can lead to challenges and potential invalidation of the patent.

Patent Term Adjustments and Terminal Disclaimers

Patent Term Adjustments (PTA)

PTA can extend the term of a patent due to delays in the patent office's processing. However, as seen in In re Cellect LLC, any PTA must be considered in the context of ODP and terminal disclaimers. This ensures that the patent term does not extend beyond what is legally permissible[1].

Terminal Disclaimers

Terminal disclaimers are often used to overcome ODP rejections by disclaiming the term of the later patent that extends beyond the term of the earlier patent. This can affect the overall term and validity of RE33239 if such disclaimers are necessary.

Examination Process and Patent Quality

Narrowing of Claims

The patent examination process tends to narrow the scope of patent claims, both in terms of claim length and claim count. This narrowing can increase the likelihood of patent grant and reduce the examination duration[3].

Implications for RE33239

If RE33239 underwent significant changes during the reissue process, it is important to analyze how these changes affected its scope and validity. Narrower claims may enhance the patent's chances of survival but could also limit its market impact.

Market Impact and Strategic Considerations

Licensing and Litigation

The scope and claims of RE33239 will significantly influence its market value and the potential for licensing and litigation. Broader, yet clearer claims can provide stronger protection but may also attract more challenges.

Competitive Landscape

Understanding the competitive landscape is crucial. Analyzing how RE33239 fits into the existing patent landscape can help in strategizing its use, whether for defensive purposes or as a tool for market domination.

Case Law and Precedents

Relevant Cases

Cases like Merck & Co. v. Hi-Tech Pharmacal Co. and AbbVie Inc. v. Mathilda & Terence Kennedy Institute of Rheumatology Trust provide valuable insights into how courts interpret ODP, PTA, and terminal disclaimers. These precedents can guide the analysis and strategy for RE33239[1].

Presumption of Validity

35 USC 282

Each claim of a patent is presumed valid, but this presumption can be challenged. Ensuring that the claims of RE33239 are well-supported and clear is essential to maintaining this presumption of validity[5].

Key Takeaways

  • Patent Scope: Analyze the claims using metrics like independent claim length and count to understand the breadth and depth of protection.
  • ODP: Ensure that the claims are not obvious variants of prior patents to avoid ODP issues.
  • Inventorship: Verify that the listed inventors are the true and sole inventors to avoid challenges.
  • PTA and Terminal Disclaimers: Consider these factors in the context of ODP to ensure the patent term is legally permissible.
  • Examination Process: Understand how the examination process may have narrowed the claims and its implications.
  • Market Impact: Assess the market value and potential for licensing and litigation based on the patent's scope and claims.

FAQs

Q: What is the significance of ODP in patent law? A: ODP prevents an inventor from securing a second, later-expiring patent for an invention that is obvious in view of a prior patent, ensuring that the patent term does not extend indefinitely.

Q: How do terminal disclaimers affect patent term? A: Terminal disclaimers disclaim the term of a later patent that extends beyond the term of an earlier patent, ensuring compliance with ODP rules and preventing extended patent terms.

Q: What metrics are used to measure patent scope? A: Metrics such as independent claim length and independent claim count are commonly used to measure patent scope.

Q: Why is inventorship important in patent law? A: Accurate inventorship is crucial to ensure that the true and sole inventors are credited, as misattribution can lead to challenges and potential invalidation of the patent.

Q: How does the patent examination process affect patent claims? A: The examination process tends to narrow the scope of patent claims, increasing the likelihood of patent grant and reducing the examination duration.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent RE33239

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE33239

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 1230056 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.